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Seasonal influenza vaccination coverage in most EU/EEA remains suboptimal. Providers’ and users’ confidence in
influenza vaccines is undermined by reports of moderate to low vaccine effectiveness and by the lack of solid
evidence on disease burden. A study from Preaud and co. indicates that even with current levels of vaccine
effectiveness, increasing vaccination coverage would significantly reduce disease burden and health cost. The
results of the study should be interpreted cautiously because some of the assumptions are not generalizable or are
imprecise, especially those on vaccine coverage, disease burden and health cost. Increasing vaccination coverage in
EU/EEA countries is very challenging. Multifaceted approaches and country specific strategies are needed to
address vaccine hesitancy in health care workers and in the population, and to manage organisational and financial
obstacles. One key element for increasing vaccination coverage is the development of better influenza vaccines, e.g.
vaccines that are more effective, provide longer lasting immunity and do not require annual administration. Vaccine
producers should consider this as the highest research priority in the field of influenza vaccine development.
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Influenza viruses are characterized by continuous anti-
genic evolutions; thus, annual revaccination is needed to
maintain an adequate level of immunological protection
among those at risk of severe illness. In order to plan
vaccination programmes, updated information on dis-
ease burden and associated costs, vaccination coverage,
reasons for vaccine hesitancy and low coverage at popu-
lation level, and risk/benefit analysis of vaccination is
needed. At EU/EEA level, such information is often dif-
ficult to obtain, due to heterogeneity among Member
States in the availability of resources, quality of surveil-
lance systems, and comprehensive vaccination registries.
Despite the 2009 European Council recommendations
[1], seasonal influenza vaccination coverage in EU/EEA
is mostly suboptimal, with some countries being very far
from the target of 75% coverage in older individuals and
in other target groups [2].
In this issue of BMC Public Health, Preaud and col-
leagues from vaccine producer firms report estimates of* Correspondence: Bruno.Ciancio@ecdc.europa.eu
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article, unless otherwise stated.the annual impact of influenza epidemics in terms of
morbidity/mortality and offset costs for 27 EU/EEA
countries [3]. The study provides insights into current
Influenza vaccine coverage gaps and possible benefits of
increasing coverage levels. The authors estimated that
additional 57.4 million individuals should be vaccinated
every year to achieve 75% coverage in the target groups:
between 1.6 and 1.7 million influenza cases would be
prevented each year, as well as more than half million
general practitioners visits, 23,800-31,400 hospitalisa-
tions, 9,800-14,300 deaths, and almost 1 million lost days
of work. As expected, the highest impact in terms of
averted hospitalisations and deaths would be among
individuals older than 64 years. Overall, between € 190
million and € 226 million yearly would be saved.
Due to the lack of country specific data for many EU/
EEA countries included, the results of the study were
based on a number of assumptions and extrapolations.
Annual influenza attack rates by risk group were de-
rived from the placebo arms of randomised controlled
trials, with overrepresentation of healthy adults and chil-
dren. Country specific data on disease burden by risk
group and offset costs were available from few countries
and extrapolated to the others based on geographicalentral Ltd. This is an Open Access article distributed under the terms of the
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enza related hospitalisations and mortality data are also
very scanty, and estimating the burden of disease as the
excess of all-cause hospitalisations and deaths may have
led to an overestimation, whereas using Eurostat case-
specific events may have led to an underestimation of the
burden, because very few influenza deaths and hospitalisa-
tions are recorded as such. In addition the study tends to
underestimate the disease burden in children, pregnant
women and young adults with underlying conditions.
Using disability-adjusted life years (DALYs) instead of
morbidity/mortality, would have better accounted for pre-
mature mortality (years of life lost) and long term sequelae
in these groups. Vaccine coverage figures were obtained
from published sources, when available, and extrapolated
for all countries and risk groups for which information
was not available. Vaccination coverage figures in Europe
are quite reliable for individuals older than 64 years, but
much less for other target groups. Only few countries have
comprehensive vaccination registries and few ad hoc stud-
ies are available to provide reliable figures. Thus, the esti-
mation of the vaccine gap is likely to be imprecise.
Analyses were performed separately for vaccine effec-
tiveness, vaccine efficacy and their upper and lower 95%
confidence intervals (CI), and by age group and presence
of underlying conditions. Overall vaccine effectiveness es-
timates were obtained from a single US study performed
during the 2010/11 influenza season where co-circulation
of influenza A (H1N1), A(H3N2) and B was observed [4].
Estimates ranged from 56% (95% CI: 31 to 74) among chil-
dren 6 months-2 years of age to 36% (95% CI: 22 to 66)
among subjects ≥65 years. Ninety five percent CI were ob-
tained from two European studies performed during the
same [5] and the following season [6] when there was
dominance of influenza A(H1N1) and A (H3N2), respect-
ively. Vaccine efficacy values and their 95% CI were ob-
tained from Cochrane literature reviews. Although these
estimates are based on valid studies, vaccine effectiveness
estimates are season- and strain-specific (due to factors
such as variations in the vaccine/virus match and the time
between vaccination and exposure), thus affecting the
generalizability of the figures on averted cases and costs.
Despite these limitations, we agree with the conclu-
sions of the study that even with suboptimal vaccine ef-
fectiveness, the benefits of increasing vaccination coverage
would be enormous in terms of averted morbidity, morta-
lity and cost. It is therefore important to mention some of
the main reasons for low vaccine coverage in EU/EEA
countries:
1. Vaccine hesitancy in health care workers (HCW)
and in the population. According to the annual
surveys conducted by ECDC through the VENICE
network, vaccination coverage among HCWs is verylow in EU and EEA countries [2]. The motivation of
HCW plays an important role in the effectiveness of
influenza vaccination programmes. Doubts about
vaccine effectiveness and/or safety [7-10] and disease
severity [9,11] are the main reasons for HCW
refusing seasonal vaccination. HCW with these
concerns are also less likely to recommend
vaccination to their patients.
2. Lack of confidence in vaccine effectiveness and
safety. In recent years, also due to limited availability
of high quality evidence [12] and controversial
publications on vaccine effectiveness [13,14],
Europe has experienced a surge of doubts about
effectiveness of influenza vaccines. Reliable systems
should be further implemented to monitor vaccine
effectiveness and safety [15-17], in order to build
trust in influenza vaccines among HCW and the
general population.
3. Complex vaccine recommendations. Higher
vaccination coverage among elderly compared to
other target groups are also explained by a clear age
cut-off defining this group. Among other reasons
(i.e., to reduce virus circulation in the community),
these considerations have led the US Centers for
Disease Control and Prevention to recommend
universal vaccination of the population older than
5 months of age in the US [18]. This is also a way to
indirectly reach those with underlying conditions in
some population groups [19].
4. Short vaccine delivery window. Most influenza
vaccination campaigns aim at administering the
seasonal vaccine to the highest number of eligible
subjects during a short time window preceding the
start of the flu season. To overcome organisational
challenges, vaccination should also be encouraged
during the entire influenza season.
5. Lack of resources. In a time of severe financial
constraints and in the absence of strong data on
influenza burden and effectiveness of vaccination, it
is difficult for many EU/EEA countries to prioritise
influenza prevention over other perceived more
pressing health issues.
In conclusion, seasonal influenza vaccination is the
single most effective protective measure against influ-
enza. In order to maximise the effectiveness of influenza
vaccination programmes vaccination coverage should be
monitored more effectively in EU/EEA countries using
vaccination registries or other administrative methods in
combination with periodic population surveys. This may
facilitate identification of the groups where vaccine co-
verage is low and the reasons for being unvaccinated, in
order to inform targeted interventions to increase cover-
age. Surveillance systems should be strengthened to
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risk group. Vaccine effectiveness and safety monitoring
should be ensured at EU/EEA level, rising population
and HCW trust on recommended interventions. Finally,
research on immunological correlates of protection is
needed to stimulate development of more effective vac-
cines (e.g. wider/universal strain coverage and longer
lasting immunity) and to increase their acceptance by
doctors and patients. This research is expensive and un-
affordable for most public health agencies and requires
stronger financial commitments from the private sector.
Vaccine producers should consider this as the highest
research priority in the field of influenza vaccine devel-
opment [20].
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